Document is current
Any future updates will be listed below
-
Authors
Chen, Yu-Wei
Rini, Brian I.
-
Funding
Funding for this research was provided by:
National Institutes of Health (T32 CA160056)
- License Information
-
More Information
Article History
Accepted: 30 September 2021
First Online: 5 March 2022
Declarations
:
: Yu-Wei Chen declares that he has no conflict of interest. Brian I. Rini has received research funding (paid to his institution) from Pfizer, Hoffman-LaRoche, Incyte Corporation, AstraZeneca, TARIS Biomedical, Seattle Genetics, Arrowhead Pharmaceuticals, Immunomedics, Bristol-Myers Squibb, Mirati Therapeutics, Merck, Surface Oncology, Dragonfly Therapeutics, Aravive, and Exelixis; has received compensation for service as a consultant from Bristol-Myers Squibb, Pfizer, Genentech/Roche, Aveo Oncology, Synthorx, Compugen, Merck, Corvus Pharmaceuticals, Surface Oncology, 3D Medicines, Aravive, Alkermes, Arrowhead Pharmaceuticals, GlaxoSmithKline, Shionogi, Eisai, and NiKang Therapeutics; and owns stock in PTC Therapeutics.
